• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background The clinical relevance of genetic variants in nonischemic dilated
cardiomyopathy (DCM) is unsettled. Objectives The study sought to assess the prognostic …

Background Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to
5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and …

Simple Summary Cardiolaminopathies portend an augmented risk of atrial and ventricular
arrhythmias, thromboembolic events, ventricular dysfunction, and mortality. A high level of …

BACKGROUND: LMNA (lamin A/C)-related dilated cardiomyopathy is a rare genetic cause
of heart failure. In a phase 2 trial and long-term extension, the selective p38α MAPK …

Background Desmin (DES) pathogenic variants cause a small proportion of arrhythmogenic
cardiomyopathy (ACM). Outcomes data on DES-related ACM are scarce. Objectives This …

Background LMNA genotype-positive patients have high risk of experiencing life-threatening
ventricular tachyarrhythmias (VTAs). The LMNA-risk VTA calculator published in 2019 has …

Aims Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are
increasingly recognized as risk markers for adverse outcomes in non‐ischaemic dilated …

Aims LMNA‐related dilated cardiomyopathy (DCM) is a rare disease with an incompletely
defined phenotype. The phase 3 REALM‐DCM trial evaluated a potential disease‐modifying …

Abstract Purpose of Review Dilated cardiomyopathy (DCM) is one of the most prevalent
primary cardiomyopathies and may be caused by genetic and non-genetic etiologies. DCM …